Ebola Outbreak in DRC Surges, Reaching 3,200 Cases, Oxford Vaccine Trial Underway BODY: Kampala, Uganda – The Democratic Republic of Congo (DRC) is addressing its 17th Ebola outbreak, with the confirmed case count now exceeding 3,200, including over 1,400 deaths.
The outbreak, caused by the Bundibugyo strain of the virus, has been particularly severe, with authorities noting a surge of around 1,000 cases in just 10 days.
The situation is further complicated by the ongoing conflict in the eastern region, which has hindered response efforts. Cases have been confirmed across five provinces, with the north-eastern province of Ituri being the hardest hit, accounting for nearly 90% of the cases.
The World Health Organization (WHO) has warned that the true number of cases could be as high as four times the official tally, with eight of the ten health zones at greatest risk located in Ituri.
In a significant development, Oxford University announced that the first volunteer group has received an experimental vaccine specifically targeting the Bundibugyo strain.
The vaccine candidate was developed in just eight weeks, a testament to the collaborative efforts of researchers. Alongside this, several other candidate vaccines are being fast-tracked for clinical trials, and two potential treatments are also under development.
The WHO’s declaration of the outbreak as a public health emergency of international concern underscores the urgency of the situation.
The PARTNERS clinical trial, sponsored by the WHO, aims to assess the effectiveness of monoclonal antibody MBP134 and remdesivir as treatments for the Bundibugyo virus disease. This trial is crucial, as there are currently no approved vaccines or specific treatments available for the strain.
The outbreak’s rapid spread and the humanitarian crisis in the DRC have raised concerns about the potential for the virus to spread beyond the affected regions.
The WHO and other international organizations are working closely with the DRC and Uganda governments to strengthen surveillance, contact tracing, clinical preparedness, and management, as well as the delivery of supplies and community engagement.
As the situation continues to evolve, the world watches with hope for a breakthrough in the fight against the Bundibugyo strain of Ebola.
The success of the PARTNERS clinical trial and the effectiveness of the treatments being tested will be crucial in determining the outcome of this public health emergency.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: rfi
Source: RFI
